National Health (Price and Special Patient Contribution) Amendment Determination 2019 (No. 4) (PB 35 of 2019) (Cth)

Case

PB 35 of 2019

National Health (Price and Special Patient Contribution) Amendment Determination 2019 (No. 4)

National Health Act 1953

___________________________________________________________________________

I, SEAN LANE, Acting Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Determination under section 85B of the National Health Act 1953.

Dated           29 April 2019

SEAN LANE

Acting Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

_________________________________________________________________________

  1. Name of Instrument

(1)This Instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2019 (No. 4).

(2)This Instrument may also be cited as PB 35 of 2019.

  1. Commencement

This Instrument commences on 1 May 2019.

  1. Amendment of National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010)

Schedule 1 amends the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010).

Schedule 1     Amendments

  1. Schedule 1, entry for Olmesartan in the form Tablet containing olmesartan medoxomil 20 mg

(a)   omit from the column headed “Determined Price”:   5.63        substitute:             4.34

(b)omit from the column headed “Claimed Price”:   8.88        substitute:             6.85

  1. Schedule 1, entry for Olmesartan in the form Tablet containing olmesartan medoxomil 40 mg

(a)omit from the column headed “Determined Price”:   11.94     substitute:             9.21

(b)omit from the column headed “Claimed Price”:   15.20     substitute:             11.73

  1. Schedule 1, entry for Olmesartan with hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg

(a)omit from the column headed “Determined Price”:   7.07        substitute:             5.75

(b)omit from the column headed “Claimed Price”:   8.93        substitute:             7.26

  1. Schedule 1, entry for Olmesartan with hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg

(a)omit from the column headed “Determined Price”:   13.38     substitute:             10.65

(b)omit from the column headed “Claimed Price”:   15.24     substitute:             12.13

  1. Schedule 1, entry for Olmesartan with hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg

(a)omit from the column headed “Determined Price”:   14.81     substitute:             12.04

(b)omit from the column headed “Claimed Price”:   16.67     substitute:             13.55

Actions
Download as PDF Download as Word Document
Cases Citing This Decision

0

Cases Cited

0

Statutory Material Cited

0